AFT Pharmaceuticals Ltd. AI Stock Analysis
Want to see NZ:AFT full AI Analyst Report?
AFT Pharmaceuticals Ltd. (AFT) AI Stock Analysis
AFT Pharmaceuticals Ltd.
(NZX:AFT)
The score is primarily held back by the sharp downturn in the latest cash flow results and related balance-sheet risk (higher debt alongside negative free cash flow), despite strong revenue growth and stable gross margins. Technical indicators are broadly neutral and valuation appears relatively expensive, which limits upside without a clear improvement in cash generation and profitability.
AFT Pharmaceuticals Ltd. (AFT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- NZD 370.21M
- Dividend Yield
- 0.64%
- Average Volume (3M)
- 20.07K
- Price to Earnings (P/E)
- 32.5
- Beta (1Y)
- -0.09
- Revenue Growth
- 22.44%
- EPS Growth
- 23.14%
- Country
- NZ
- Employees
- 126
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
AFT Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
AFT Pharmaceuticals, along with its subsidiaries, focuses on the creation and distribution of pharmaceutical products across New Zealand, Australia, Asia, and other global markets. Their extensive product range addresses a variety of health categorie...
How the Company Makes Money
AFT primarily makes money by commercialising pharmaceutical products and earning revenue from selling those products into various markets. Key revenue streams typically include: (1) Direct product sales where AFT markets and distributes its own brand...
AFT Pharmaceuticals Ltd. Financial Statement Overview
Summary
Strong multi-year revenue growth and resilient gross margins are positives, but the latest period shows meaningful deterioration in cash generation (negative operating and free cash flow) alongside margin compression and a step-up in total debt, increasing near-term financial risk.
Income Statement
72PositiveBalance Sheet
66PositiveCash Flow
38Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 254.71M | 254.71M | 205.49M | 195.41M | 155.82M | 129.83M |
| Gross Profit | 110.55M | 110.55M | 89.19M | 88.27M | 72.16M | 61.30M |
| EBITDA | 28.85M | 28.55M | 21.52M | 27.72M | 20.40M | 21.12M |
| Net Income | 14.73M | 14.73M | 11.96M | 15.61M | 10.65M | 19.85M |
Balance Sheet | ||||||
| Total Assets | 217.01M | 217.01M | 169.81M | 165.26M | 148.06M | 121.76M |
| Cash, Cash Equivalents and Short-Term Investments | 10.24M | 10.24M | 11.11M | 12.04M | 4.75M | 7.94M |
| Total Debt | 54.11M | 54.11M | 30.00M | 32.19M | 38.05M | 40.51M |
| Total Liabilities | 107.94M | 107.94M | 72.74M | 77.46M | 74.80M | 65.02M |
| Stockholders Equity | 110.28M | 110.28M | 97.64M | 87.80M | 73.27M | 56.74M |
Cash Flow | ||||||
| Free Cash Flow | -11.87M | -11.87M | 6.22M | 16.02M | -173.00K | 6.64M |
| Operating Cash Flow | -11.75M | -11.75M | 13.18M | 25.55M | 9.00M | 12.22M |
| Investing Cash Flow | -9.76M | -9.76M | -6.95M | -9.53M | -9.18M | -5.58M |
| Financing Cash Flow | 11.01M | 11.01M | -6.81M | -10.63M | -6.98M | -3.91M |
AFT Pharmaceuticals Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:AFT, the sentiment is Positive. The current price of 4.59 is above the 20-day moving average (MA) of 4.59, above the 50-day MA of 4.48, and above the 200-day MA of 4.00, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 52.86 is Neutral, neither overbought nor oversold. The STOCH value of 64.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NZ:AFT.
AFT Pharmaceuticals Ltd. Peers Comparison
Overall Rating
NZ:FPH80Outperform
NZ:EBO56Neutral
NZ:AFT54Neutral
NZ:PEB42Neutral
NZ:RUA41.5Neutral
NZ:TRU37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | NZD 29.03B | 61.61 | 22.84% | 1.24% | 15.59% | 23.94% | |
| 56Neutral | NZD 4.54B | 16.71 | 7.99% | 5.69% | 16.36% | 5.52% | |
| 54Neutral | NZD 485.57M | 32.46 | 14.07% | 0.64% | 22.44% | 23.14% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 42Neutral | NZD 341.52M | -6.66 | -190.54% | ― | -47.36% | -3.79% | |
| 42Neutral | NZD 11.77M | -2.60 | ― | ― | 70.82% | 41.04% | |
| 37Underperform | NZD 8.38M | -2.58 | -75.57% | ― | 42.20% | 23.68% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NZ:AFT | AFT Pharmaceuticals Ltd. | 4.59 | 0.93 | 25.38% | |
| NZ:EBO | EBOS Group Limited | 21.65 | -5.75 | -20.98% | |
| NZ:FPH | Fisher & Paykel Healthcare Corporation Limited | 49.29 | 12.57 | 34.25% | |
| NZ:PEB | Pacific Edge Limited | 0.26 | 0.07 | 40.88% | |
| NZ:TRU | TruScreen Group Ltd. | 0.01 | -0.01 | -41.18% | |
| NZ:RUA | Rua Bioscience Ltd. | 0.03 | -0.00 | -3.70% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 05, 2026
